Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project)

Cephalalgia

Volumn 34, Issue 6, 2014, Pages 426-433

  Bendtsen, L ^a   Munksgaard, S B ^a   Tassorelli, C ^b   Nappi, G ^b   Katsarava, Z ^c   Lainez, M ^d   Leston, J A ^e   Fadic, R ^f   Spadafora, S ^g   Stoppini, A ^h   Jensen, R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Foundation of the Valencian Community University Clinical Hospital   (Spain)

^e FLENI   (Argentina)

^f PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^g Universidad ISALUD   (Argentina)

^h Bioengineering and Medical Informatics Consortium ^*  (Italy)

Author keywords

anxiety; depression; detoxification; disability; management; Medication overuse headache

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ERGOT DERIVATIVE; LEVOMEPROMAZINE; METOCLOPRAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROMETHAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE;

ADULT; ANXIETY; ARTICLE; CHRONIC TENSION HEADACHE; COHORT ANALYSIS; DEPRESSION; DETOXIFICATION; DISABILITY; DRUG INDUCED HEADACHE; EPISODIC TENSION HEADACHE; FEMALE; HEADACHE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDAS (MIGRAINE); MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY (TOPIC); POLYPHARMACY; QUESTIONNAIRE; TREATMENT OUTCOME; ADDICTION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; ETIOLOGY; HEADACHE DISORDERS, SECONDARY; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ANALGESICS; ANXIETY; COHORT STUDIES; DEPRESSION; DISABILITY EVALUATION; FEMALE; HEADACHE DISORDERS, SECONDARY; HUMANS; MALE; MIDDLE AGED; SUBSTANCE-RELATED DISORDERS;

EID: 84899004856     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102413515338     Document Type: Article

References (21)

1. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: The Eurolight project. Eur J Neurol. 2012; 19: 703-711
2. Munksgaard SB, Bendtsen L, Jensen RH. Treatment-resistant medication overuse headache can be cured. Headache. 2012; 52: 1120-1129
3. Hagen K, Albretsen C, Vilming ST, et al. A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study. J Headache Pain. 2011; 12: 315-322
4. Grande RB, Aaseth K, Benth JS, et al. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011; 18: 129-137
5. Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. structured detoxification programmes for medication overuse headache: A prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006; 26: 1097-1105
6. Munksgaard SB, Bendtsen L, Jensen RH. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: A comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012; 32: 834-844
7. Lanteri-Minet M, Duru G, Mudge M, et al. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review. Cephalalgia. 2011; 31: 837-850
8. Wallasch TM, Kropp P. Multidisciplinary integrated headache care: A prospective 12-month follow-up observational study. J Headache Pain. 2012; 13: 521-529
9. Raggi A, Giovannetti AM, Leonardi M, et al. Disability and mood state in patients with episodic and chronic migraine associated to medication overuse. Neurol Sci. 2012; 33: S169-S171
10. Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al. Medication overuse headache: Clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007; 27: 1219-1225
11. Andrasik F, Grazzi L, Usai S, et al. Disability in chronic migraine with medication overuse: Treatment effects through 5 years. Cephalalgia. 2010; 30: 610-614
12. Stewart WF, Lipton RB, Kolodner K, et al. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999; 19: 107-114
13. Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001; 56: S20-S28
14. Edmeads J, Láinez JM, Brandes JL, et al. Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. Neurology. 2001; 56: S29-S34
15. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002; 52: 69-77
16. Maizels M, Smitherman TA, Penzien DB. A review of screening tools for psychiatric comorbidity in headache patients. Headache. 2006; 46: S98-S109
17. Peng KP, Wang SJ. Migraine diagnosis: Screening items, instruments, and scales. Acta Anaesthesiol Taiwan. 2012; 50: 69-73
18. Bøe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: Predictors of outcome 1 year after withdrawal therapy. Eur J Neurol. 2009; 16: 705-712
19. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746
20. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24: 1-160
21. Andrasik F, Grazzi L, Usai S, et al. Disability in chronic migraine with medication overuse: Treatment effects at 3 years. Headache. 2007; 47: 1277-1281